至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

MiR-34a Inhibits Breast Cancer Proliferation and Progression by Targeting Wnt1 in Wnt/β-Catenin Signaling Pathway.

Am J Med Sci. 2016; 
Si W, Li Y, Shao H, Hu R, Wang W, Zhang K, Yang Q.
Products/Services Used Details Operation
Custom Vector Construction Dual-luciferase report assay As suggested by the predicted interaction between the miR-34a and 3’-UTR of Wnt1, either the wild type 3’-UTR of Wnt1 or mutated 3’-UTR of Wnt1 was cloned into the downstream of the luciferase reporter gene contained in the pGL3 promoter vector (Genscript, Nanjing, China). Get A Quote

摘要

As microRNA-34a (miR-34a) has been suggested to be associated with breast cancer (BC), this study was proposed to explore the underlying mechanism of miR-34a in suppressing BC progression.,A total of 123 pairs of tumor tissues and matched nontumor tissues were obtained from patients. Reverse transcription polymerase chain reaction and in situ hybridization were used to detect the differences in miR-34a expression in tissues and cells. Whether Wnt1 is a direct downstream target of miR-34a was confirmed by both bioinformatics target gene prediction and dual-luciferase report assay. Wnt1 and other gene expressions that are related to Wnt/β-catenin signaling pathway were assessed by reverse transcription polymeras... More

关键词

Breast cancer; Wnt/β-catenin signaling pathway; Wnt1; Xenograft model; microRNA-34a